The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Chotivanich, Kesinee ^a   Mungthin, Mathirut ^b   Ruengweerayuth, Ronnatrai ^c   Udomsangpetch, Rachanee ^d   Dondorp, Arjen M ^a   Singhasivanon, Pratap ^a   Pukrittayakamee, Sasithon ^a   White, Nicholas J ^a,e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c MAE SOT GENERAL HOSPITAL   (Thailand)

^d Mahidol University   (Thailand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti malarial drugs; In vitro susceptibility; Malaria

Indexed keywords

ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; HYPOXANTHINE; LIPID; TRIACYLGLYCEROL;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG EFFICACY; HYPERLIPIDEMIA; IC 50; IN VITRO STUDY; LIPID BLOOD LEVEL; NONHUMAN; PLASMODIUM FALCIPARUM; POSTPRANDIAL STATE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIMALARIALS; ATOVAQUONE; ETHANOLAMINES; FLUORENES; HUMAN EXPERIMENTATION; HUMANS; INHIBITORY CONCENTRATION 50; LIPIDS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; SERUM;

EID: 84861439370     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-177     Document Type: Article

References (25)

1. The origins and spread of antimalarial drug resistance: lessons for policy makers. Anderson TJ, Roper C, Acta Trop 2005 94 269 280 10.1016/j.actatropica.2005.04.010 15878153 (Pubitemid 40720332)
2. Antimalarial drug resistance. White NJ, J Clin Invest 2004 113 1084 1092 15085184 (Pubitemid 38544090)
3. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH, Trans R Soc Trop Med Hyg 1992 86 121 122 10.1016/0035-9203(92)90531-G 1440763
4. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Baird JK, Sustriayu Nalim MF, Basri H, Masbar S, Leksana B, Tjitra E, Dewi RM, Khairani M, Wignall FS, Trans R Soc Trop Med Hyg 1996 90 409 411 10.1016/S0035-9203(96)90526-X 8882190 (Pubitemid 26335969)
5. Plasmodium vivax clinically resistant to chloroquine in Colombia. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedẽo N, Dunne M, Berman J, Am J Trop Med Hyg 2001 65 90 93 11508397 (Pubitemid 32744210)
6. Chloroquine resistant Plasmodium vivax malaria in India. Dua VK, Kar PK, Sharma VP, Trop Med Int Health 1996 1 816 819 8980595 (Pubitemid 27010563)
7. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ, Acta Trop 2004 89 351 356 10.1016/j.actatropica.2003.10.012 14744561 (Pubitemid 38117071)
8. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP, Malar J 2009 8 253 10.1186/1475-2875-8-253 19906307
9. Antimalarial dosing regimens and drug resistance. Barnes KI, Watkins WM, White NJ, Trends Parasitol 2008 24 127 134 10.1016/j.pt.2007.11.008 18262470
10. A collaborative epidemiological investigation into the criminal fake artesunatetrade in South East Asia. Newton PN, Fernández FM, Plançon A, Mildenhall DC, Green MD, Ziyong L, Christophel EM, Phanouvong S, Howells S, McIntosh E, Laurin P, Blum N, Hampton CY, Faure K, Nyadong L, Soong CW, Santoso B, Zhiguang W, Newton J, Palmer K, PLoS Med 2008 5 32 10.1371/journal.pmed.0050032 18271620 (Pubitemid 351317652)
11. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lell B, Luckner D, Ndjavé M, Scott T, Kremsner PG, Lancet 1998 351 709 713 10.1016/S0140-6736(97)09222-2 9504515 (Pubitemid 28105340)
12. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q, Antimicrob Agents Chemother 2000 44 2100 2108 10.1128/AAC.44.8.2100-2108.2000 10898682 (Pubitemid 30484433)
13. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J, Br J Clin Pharmacol 1994 37 13 20 10.1111/j.1365-2125.1994.tb04232.x 8148213 (Pubitemid 24204575)
14. Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH, Ann Pharmacother 1998 32 1004 1007 10.1345/aph.17464 9793589 (Pubitemid 28498457)
15. Food-drug interactions. Schmidt LE, Dalhoff K, Drugs 2002 62 1481 1502 10.2165/00003495-200262100-00005 12093316 (Pubitemid 34804156)
16. How much fat is necessary to optimize lumefantrine oral bioavailability? Ashley EA, Stepniewska K, Lindegårdh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F, Trop Med Int Health 2007 12 195 200 10.1111/j.1365-3156.2006.01784.x 17300625
17. In vitro activity of lumefantrine (Benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Basco LK, Bickii J, Ringwald P, Antimicrob Agents Chemother 1998 42 2347 2351 9736561 (Pubitemid 28420376)
18. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F, Trans R Soc Trop Med Hyg 2000 94 537 544 10.1016/S0035-9203(00)90080-4 11132385
19. Human malaria parasites in continuous culture. Trager W, Jensen JB, Science 1976 193 673 675 10.1126/science.781840 781840
20. 50 of halofantrine against Plasmodium falciparum. Humberstone AJ, Cowman AF, Horton J, Charman WN, J Pharm Sci 1998 87 256 258 10.1021/js970279q 9519163 (Pubitemid 28081337)
21. Altered plasma lipid pattern in falciparum malaria. Mohanty S, Mishra SK, Das BS, Satpathy SK, Mohanty D, Patnaik JK, Bose TK, Ann Trop Med Parasitol 1992 86 601 606 1304701 (Pubitemid 23090619)
22. Cardiac complications of halofantrine: a prospective study of 20 patients. Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, Le Bras M, Trans R Soc Trop Med Hyg 1995 89 430 433 10.1016/0035-9203(95)90041- 1 7570888
23. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White NJ, Nosten F, Antimicrob Agents Chemother 1998 42 135 139 9449273 (Pubitemid 28053339)
24. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. van Vugt MV, Wilairatana P, Gemperli B, Gathmam I, Phipum L, Brockman A, Luxemburger C, White NJ, Nosten F, Looareesuwan S, Am J Trop Med Hyg 1999 60 936 942 10403324 (Pubitemid 29296218)
25. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, Baret E, Fusa T, Rogier C, Pradines B, Antimicrob Agents Chemother 2009 53 2248 2252 10.1128/AAC.01462-08 19307369